Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
Unknown unknown
|
Hodgkin's lymphoma
|
not applicable |
Brentuximab vedotin + Umbralisib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, the combination of TGR-1202 and Brentuximab vedotin synergized to inhibit proliferation of several human Hodgkin's lymphoma cell lines in culture and to suppress tumor growth in xenograft models (Blood 124(21): 4486).
|
detail...
|